Advertisement

Plasma Levels of Endothelial Microparticles Bearing Monomeric C-reactive Protein are Increased in Peripheral Artery Disease

  • Jeffrey R. Crawford
  • JoAnn TrialEmail author
  • Vijay Nambi
  • Ron C. Hoogeveen
  • George E. Taffet
  • Mark L. Entman
Original Article

Abstract

C-reactive protein (CRP) as an indicator of cardiovascular disease (CVD) has shown limited sensitivity. We demonstrate that two isoforms of CRP (pentameric, pCRP and monomeric, mCRP) present in soluble form or on microparticles (MPs) have different biological effects and are not all measured by clinical CRP assays. The high-sensitivity CRP assay (hsCRP) did not measure pCRP or mCRP on MPs, whereas flow cytometry did. MPs derived from endothelial cells, particularly those bearing mCRP, were elevated in peripheral artery disease (PAD) patients compared to controls. The numbers of mCRP+ endothelial MPs did not correlate with hsCRP measurements of soluble pCRP, indicating their independent modulation. In controls, statins lowered mCRP+ endothelial MPs. In a model of vascular inflammation, mCRP induced endothelial shedding of MPs and was proinflammatory, while pCRP was anti-inflammatory. mCRP on endothelial MPs may be both an unmeasured indicator of, and an amplifier of, vascular disease, and its detection might improve risk sensitivity.

Keywords

CRP Peripheral artery disease Monomeric CRP Pentameric CRP hsCRP Inflammation Microparticle 

Abbreviations

CRP

C-reactive protein

hsCRP

high-sensitivity CRP assay

mCRP

monomeric CRP

MNL

mononuclear leukocyte

MP

microparticle

PAD

peripheral artery disease

pCRP

pentameric CRP

TEM

transendothelial migration

Notes

Acknowledgments

We are grateful for the CRP antibody donation of Dr. Larry Potempa (Roosevelt University, Chicago, Illinois). We would like to thank all subjects who participated in the study, Tenille Epperson and Joe L. Raya for their technical assistance and the MD Anderson Cancer Center Flow Cytometry Core for their assistance with the Amnis cytometer.

Compliance with Ethical Standards

The study was conducted in accordance with the ethical standards of the Helsinki declaration and its later amendments and with the ethical standards and approval of the Institutional Review Board of Baylor College of Medicine. Informed consent was obtained from all individual participants included in the study. No animal studies were carried out by the authors for this article.

Sources of Funding

This work was supported by the National Institutes of Health [T32AI053831-10 to J.R.C., RO1 HL-089792 to M.L.E.], Bethesda, Maryland; the Hankamer Foundation, Houston, Texas; the Vivian L. Smith Foundation, Houston, Texas; and The Medallion Foundation, Houston, Texas.

Conflict of Interest

V.N. and R.C.H. are co-investigators on a provisional patent filed by Roche for use of biomarkers in heart failure prediction. The other authors declare that this research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. V.N. has indicated that he has served on the regional advisory board (once) for Sanofi-Regeneron.

Supplementary material

12265_2016_9678_MOESM1_ESM.pdf (726 kb)
ESM 1 (PDF 725 kb)

References

  1. 1.
    Ansar, W., & Ghosh, S. (2013). C-reactive protein and the biology of disease. Immunologic Research, 56(1), 131–142. doi: 10.1007/s12026-013-8384-0.CrossRefPubMedGoogle Scholar
  2. 2.
    Eisenhardt, S. U., Habersberger, J., Murphy, A., Chen, Y. C., Woollard, K. J., Bassler, N., et al. (2009). Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circulation Research, 105(2), 128–137. doi: 10.1161/CIRCRESAHA.108.190611.CrossRefPubMedGoogle Scholar
  3. 3.
    Habersberger, J., Strang, F., Scheichl, A., Htun, N., Bassler, N., Merivirta, R. M., et al. (2012). Circulating microparticles generate and transport monomeric C-reactive protein in patients with myocardial infarction. Cardiovascular Research, 96(1), 64–72. doi: 10.1093/cvr/cvs237.CrossRefPubMedGoogle Scholar
  4. 4.
    Paul, A., Ko, K. W., Li, L., Yechoor, V., McCrory, M. A., Szalai, A. J., et al. (2004). C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation, 109(5), 647–655. doi: 10.1161/01.CIR.0000114526.50618.24.CrossRefPubMedGoogle Scholar
  5. 5.
    Hirschfield, G. M., Gallimore, J. R., Kahan, M. C., Hutchinson, W. L., Sabin, C. A., Benson, G. M., et al. (2005). Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proceedings of the National Academy of Sciences of the United States of America, 102(23), 8309–8314. doi: 10.1073/pnas.0503202102.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Kovacs, A., Tornvall, P., Nilsson, R., Tegner, J., Hamsten, A., & Bjorkegren, J. (2007). Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia. Proceedings of the National Academy of Sciences of the United States of America, 104(34), 13768–13773. doi: 10.1073/pnas.0706027104.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Teupser, D., Weber, O., Rao, T. N., Sass, K., Thiery, J., & Fehling, H. J. (2011). No reduction of atherosclerosis in C-reactive protein (CRP)-deficient mice. The Journal of Biological Chemistry, 286(8), 6272–6279. doi: 10.1074/jbc.M110.161414.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Mause, S. F., & Weber, C. (2010). Microparticles: protagonists of a novel communication network for intercellular information exchange. Circulation Research, 107(9), 1047–1057. doi: 10.1161/CIRCRESAHA.110.226456.CrossRefPubMedGoogle Scholar
  9. 9.
    Suades, R., Padro, T., Vilahur, G., & Badimon, L. (2012). Circulating and platelet-derived microparticles in human blood enhance thrombosis on atherosclerotic plaques. Thrombosis and Haemostasis, 108(6), 1208–1219. doi: 10.1160/TH12-07-0486.CrossRefPubMedGoogle Scholar
  10. 10.
    Leroyer, A. S., Tedgui, A., & Boulanger, C. M. (2008). Role of microparticles in atherothrombosis. Journal of Internal Medicine, 263(5), 528–537. doi: 10.1111/j.1365-2796.2008.01957.x.CrossRefPubMedGoogle Scholar
  11. 11.
    Sternik, L., Samee, S., Schaff, H. V., Zehr, K. J., Lerman, L. O., Holmes, D. R., et al. (2002). C-reactive protein relaxes human vessels in vitro. Arteriosclerosis, Thrombosis, and Vascular Biology, 22(11), 1865–1868.CrossRefPubMedGoogle Scholar
  12. 12.
    Khreiss, T., Jozsef, L., Potempa, L. A., & Filep, J. G. (2004). Opposing effects of C-reactive protein isoforms on shear-induced neutrophil-platelet adhesion and neutrophil aggregation in whole blood. Circulation, 110(17), 2713–2720. doi: 10.1161/01.CIR.0000146846.00816.DD.CrossRefPubMedGoogle Scholar
  13. 13.
    Molins, B., Pena, E., Vilahur, G., Mendieta, C., Slevin, M., & Badimon, L. (2008). C-reactive protein isoforms differ in their effects on thrombus growth. Arteriosclerosis, Thrombosis, and Vascular Biology, 28(12), 2239–2246. doi: 10.1161/ATVBAHA.108.174359.CrossRefPubMedGoogle Scholar
  14. 14.
    Khreiss, T., Jozsef, L., Potempa, L. A., & Filep, J. G. (2004). Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation, 109(16), 2016–2022. doi: 10.1161/01.CIR.0000125527.41598.68.CrossRefPubMedGoogle Scholar
  15. 15.
    Khreiss, T., Jozsef, L., Potempa, L. A., & Filep, J. G. (2005). Loss of pentameric symmetry in C-reactive protein induces interleukin-8 secretion through peroxynitrite signaling in human neutrophils. Circulation Research, 97(7), 690–697. doi: 10.1161/01.RES.0000183881.11739.CB.CrossRefPubMedGoogle Scholar
  16. 16.
    Zouki, C., Haas, B., Chan, J. S., Potempa, L. A., & Filep, J. G. (2001). Loss of pentameric symmetry of C-reactive protein is associated with promotion of neutrophil-endothelial cell adhesion. Journal of Immunology, 167(9), 5355–5361.CrossRefGoogle Scholar
  17. 17.
    Mok, C. C., Ying, S. K., Ma, K. M., & Wong, C. K. (2013). Effect of raloxifene on disease activity and vascular biomarkers in patients with systemic lupus erythematosus: subgroup analysis of a double-blind randomized controlled trial. Lupus, 22(14), 1470–1478. doi: 10.1177/0961203313507987.CrossRefPubMedGoogle Scholar
  18. 18.
    Kiefer, C. R., Stock, R. E., Flanagan, S. S., Darling, C. E., Smith, C. S., & Snyder, L. M. (2012). Early verification of myocardial ischemia with a novel biomarker of acute tissue damage: C-reactive protein fractional forms. Clinica Chimica Acta: International Journal of Clinical Chemistry, 413(19–20), 1536–1541. doi: 10.1016/j.cca.2012.06.023.CrossRefGoogle Scholar
  19. 19.
    Thiele, J. R., Habersberger, J., Braig, D., Schmidt, Y., Goerendt, K., Maurer, V., et al. (2014). Dissociation of pentameric to monomeric C-reactive protein localizes and aggravates inflammation: in vivo proof of a powerful proinflammatory mechanism and a new anti-inflammatory strategy. Circulation, 130(1), 35–50. doi: 10.1161/CIRCULATIONAHA.113.007124.CrossRefPubMedGoogle Scholar
  20. 20.
    Golomb, B. A., Dang, T. T., & Criqui, M. H. (2006). Peripheral arterial disease: morbidity and mortality implications. Circulation, 114(7), 688–699. doi: 10.1161/CIRCULATIONAHA.105.593442.CrossRefPubMedGoogle Scholar
  21. 21.
    Kresl, J. J., Potempa, L. A., & Anderson, B. E. (1998). Conversion of native oligomeric to a modified monomeric form of human C-reactive protein. The International Journal of Biochemistry & Cell Biology, 30(12), 1415–1426.CrossRefGoogle Scholar
  22. 22.
    Ying, S. C., Gewurz, H., Kinoshita, C. M., Potempa, L. A., & Siegel, J. N. (1989). Identification and partial characterization of multiple native and neoantigenic epitopes of human C-reactive protein by using monoclonal antibodies. Journal of Immunology, 143(1), 221–228.Google Scholar
  23. 23.
    Potempa, L. A., Siegel, J. N., Fiedel, B. A., Potempa, R. T., & Gewurz, H. (1987). Expression, detection and assay of a neoantigen (Neo-CRP) associated with a free, human C-reactive protein subunit. Molecular Immunology, 24(5), 531–541.CrossRefPubMedGoogle Scholar
  24. 24.
    Taylor, K. E., & van den Berg, C. W. (2007). Structural and functional comparison of native pentameric, denatured monomeric and biotinylated C-reactive protein. Immunology, 120(3), 404–411. doi: 10.1111/j.1365-2567.2006.02516.x.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Headland, S. E., Jones, H. R., D’Sa, A. S., Perretti, M., & Norling, L. V. (2014). Cutting-edge analysis of extracellular microparticles using ImageStream(X) imaging flow cytometry. Scientific Reports, 4, 5237. doi: 10.1038/srep05237.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Trial, J., Cieslik, K. A., Haudek, S. B., Duerrschmid, C., & Entman, M. L. (2013). Th1/M1 conversion to th2/m2 responses in models of inflammation lacking cell death stimulates maturation of monocyte precursors to fibroblasts. Frontiers in Immunology, 4, 287. doi: 10.3389/fimmu.2013.00287.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Yousuf, O., Mohanty, B. D., Martin, S. S., Joshi, P. H., Blaha, M. J., Nasir, K., et al. (2013). High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? Journal of the American College of Cardiology, 62(5), 397–408. doi: 10.1016/j.jacc.2013.05.016.CrossRefPubMedGoogle Scholar
  28. 28.
    Suades, R., Padro, T., Alonso, R., Mata, P., & Badimon, L. (2013). Lipid-lowering therapy with statins reduces microparticle shedding from endothelium, platelets and inflammatory cells. Thrombosis and Haemostasis, 110(2), 366–377. doi: 10.1160/TH13-03-0238.CrossRefPubMedGoogle Scholar
  29. 29.
    Wang, Y., Tao, J., Yang, Z., Tu, C., Xu, M. G., Wang, J. M., et al. (2005). Tumor necrosis factor-alpha induces release of endothelial microparticles from human endothelial cells. Zhonghua xin xue guan bing za zhi [Chinese Journal of Cardiovascular Diseases], 33(12), 1137–1140.Google Scholar
  30. 30.
    Devaraj, S., Kumaresan, P. R., & Jialal, I. (2011). C-reactive protein induces release of both endothelial microparticles and circulating endothelial cells in vitro and in vivo: further evidence of endothelial dysfunction. Clinical Chemistry, 57(12), 1757–1761. doi: 10.1373/clinchem.2011.169839.CrossRefPubMedGoogle Scholar
  31. 31.
    Dasgupta, S. K., Abdel-Monem, H., Niravath, P., Le, A., Bellera, R. V., Langlois, K., et al. (2009). Lactadherin and clearance of platelet-derived microvesicles. Blood, 113(6), 1332–1339. doi: 10.1182/blood-2008-07-167148.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Mobarrez, F., He, S., Broijersen, A., Wiklund, B., Antovic, A., Antovic, J., et al. (2011). Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease. Thrombosis and Haemostasis, 106(2), 344–352. doi: 10.1160/TH10-12-0810.CrossRefPubMedGoogle Scholar
  33. 33.
    Devaraj, S., Du Clos, T. W., & Jialal, I. (2005). Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects. Arteriosclerosis, Thrombosis, and Vascular Biology, 25(7), 1359–1363. doi: 10.1161/01.ATV.0000168573.10844.ae.CrossRefPubMedGoogle Scholar
  34. 34.
    Ji, S. R., Ma, L., Bai, C. J., Shi, J. M., Li, H. Y., Potempa, L. A., et al. (2009). Monomeric C-reactive protein activates endothelial cells via interaction with lipid raft microdomains. FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology, 23(6), 1806–1816. doi: 10.1096/fj.08-116962.CrossRefGoogle Scholar
  35. 35.
    Li, H. Y., Wang, J., Wu, Y. X., Zhang, L., Liu, Z. P., Filep, J. G., et al. (2014). Topological localization of monomeric C-reactive protein determines proinflammatory endothelial cell responses. The Journal of Biological Chemistry, 289(20), 14283–14290. doi: 10.1074/jbc.M114.555318.CrossRefPubMedGoogle Scholar
  36. 36.
    Stoger, J. L., Gijbels, M. J., van der Velden, S., Manca, M., van der Loos, C. M., Biessen, E. A., et al. (2012). Distribution of macrophage polarization markers in human atherosclerosis. Atherosclerosis, 225(2), 461–468. doi: 10.1016/j.atherosclerosis.2012.09.013.CrossRefPubMedGoogle Scholar
  37. 37.
    Oliveira, R. T., Silva, R. M., Teo, F. H., Mineiro, M. F., Ferreira, M. C., Altemani, A., et al. (2013). Detection of TCD4+ subsets in human carotid atheroma. Cytokine, 62(1), 131–140. doi: 10.1016/j.cyto.2013.02.004.CrossRefPubMedGoogle Scholar
  38. 38.
    Zhang, L., Liu, S. H., Wright, T. T., Shen, Z. Y., Li, H. Y., Zhu, W., et al. (2015). C-reactive protein directly suppresses Th1 cell differentiation and alleviates experimental autoimmune encephalomyelitis. Journal of Immunology, 194(11), 5243–5252. doi: 10.4049/jimmunol.1402909.CrossRefGoogle Scholar
  39. 39.
    Yanagita, T., Yamamoto, K., Ishida, S., Sonda, K., Morito, F., Saku, K., et al. (1994). Effects of simvastatin, a cholesterol synthesis inhibitor, on phosphatidylcholine synthesis in HepG2 cells. Clinical Therapeutics, 16(2), 200–208.PubMedGoogle Scholar
  40. 40.
    Prasad, K. (2006). C-reactive protein (CRP)-lowering agents. Cardiovascular Drug Reviews, 24(1), 33–50. doi: 10.1111/j.1527-3466.2006.00033.x.CrossRefPubMedGoogle Scholar
  41. 41.
    Albert, M. A., Danielson, E., Rifai, N., & Ridker, P. M. (2001). Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA : The Journal of the American Medical Association, 286(1), 64–70.CrossRefPubMedGoogle Scholar
  42. 42.
    Wang, C. Y., Liu, P. Y., & Liao, J. K. (2008). Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends in Molecular Medicine, 14(1), 37–44. doi: 10.1016/j.molmed.2007.11.004.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Antonopoulos, A. S., Margaritis, M., Lee, R., Channon, K., & Antoniades, C. (2012). Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Current Pharmaceutical Design, 18(11), 1519–1530.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Jeffrey R. Crawford
    • 1
  • JoAnn Trial
    • 1
    Email author
  • Vijay Nambi
    • 2
    • 3
    • 4
  • Ron C. Hoogeveen
    • 3
  • George E. Taffet
    • 1
  • Mark L. Entman
    • 1
  1. 1.The Division of Cardiovascular Sciences and the DeBakey Heart Center, Department of MedicineBaylor College of Medicine and Houston Methodist HospitalHoustonUSA
  2. 2.The Division of CardiologyMichael E. DeBakey Veterans Affairs Medical CenterHoustonUSA
  3. 3.The Division of Atherosclerosis and Vascular Medicine, Department of MedicineBaylor College of MedicineHoustonUSA
  4. 4.Center for Cardiovascular PreventionMethodist DeBakey Heart and Vascular CenterHoustonUSA

Personalised recommendations